Robert I. Kriebel
Keine laufenden Positionen mehr
Profil
Robert I.
Kriebel served as a Director at Elixir Pharmaceuticals, Inc. and Memory Pharmaceuticals Corp.
He was also the Chief Financial Officer & Executive Vice President at U.S.
Bioscience, Inc. and the Chief Financial Officer & Senior Vice President at Neose Technologies, Inc. Prior to that, he was the Vice President & Controller at Armour Pharmaceutical Co. and the Vice President-Investor Relations at Rorer Group, Inc. Kriebel received his undergraduate degree from Roanoke College.
Ehemalige bekannte Positionen von Robert I. Kriebel
| Unternehmen | Position | Ende |
|---|---|---|
Memory Pharmaceuticals Corp.
 Memory Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Memory Pharmaceuticals Corp. develops pharmaceutical products for the treatment of debilitating central nervous system (CNS) disorders such as Alzheimer's disease and schizophrenia. The company was founded by Axel Unterbeck in 1998 and is headquartered in Montvale, NJ. | Direktor/Vorstandsmitglied | 06.01.2009 |
Neose Technologies, Inc.
 Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | Finanzdirektor/CFO | 01.01.2005 |
U.S. Bioscience, Inc.
 U.S. Bioscience, Inc. BiotechnologyHealth Technology U.S. Bioscience, Inc. is a pharmaceutical company specializing in the development and commercialization of products for patients with cancer and AIDS and allied infections. The company has three products on the market. In addition to its headquarters, U.S. Bioscience has a manufacturing facility located in Nijmegen, The Netherlands, an analytical laboratory in Exton, PA, and a subsidiary near London to coordinate clinical trials in Europe. U.S. Bioscience, Inc. is headquartered in West Conshohocken, PA. | Finanzdirektor/CFO | 01.01.1999 |
Elixir Pharmaceuticals, Inc.
 Elixir Pharmaceuticals, Inc. Investment Trusts/Mutual FundsMiscellaneous Elixir Pharmaceuticals, Inc. operates as a holding company with interest in manufacturing and developing biopharmaceutical products for the treatment of metabolic diseases such as diabetes and obesity. The company was founded by Leonard Guarente, Cynthia J. Kenyon, Cindy Bayley, Louis Kunkel, Annibale Puca, and Thomas Perls in 1999 and is headquartered in Cambridge, MA. | Direktor/Vorstandsmitglied | - |
Rorer Group, Inc.
 Rorer Group, Inc. Pharmaceuticals: MajorHealth Technology Rorer Group, Inc. developed pharmaceutical preparations. It also manufactured and supplied medical devices. The company was headquartered in Fort Washington, PA. | Public Communications Contact | - |
Ausbildung von Robert I. Kriebel
| Roanoke College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
Neose Technologies, Inc.
Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | Health Technology |
Memory Pharmaceuticals Corp.
Memory Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Memory Pharmaceuticals Corp. develops pharmaceutical products for the treatment of debilitating central nervous system (CNS) disorders such as Alzheimer's disease and schizophrenia. The company was founded by Axel Unterbeck in 1998 and is headquartered in Montvale, NJ. | Health Technology |
U.S. Bioscience, Inc.
U.S. Bioscience, Inc. BiotechnologyHealth Technology U.S. Bioscience, Inc. is a pharmaceutical company specializing in the development and commercialization of products for patients with cancer and AIDS and allied infections. The company has three products on the market. In addition to its headquarters, U.S. Bioscience has a manufacturing facility located in Nijmegen, The Netherlands, an analytical laboratory in Exton, PA, and a subsidiary near London to coordinate clinical trials in Europe. U.S. Bioscience, Inc. is headquartered in West Conshohocken, PA. | Health Technology |
| Armour Pharmaceutical Co. | |
Rorer Group, Inc.
Rorer Group, Inc. Pharmaceuticals: MajorHealth Technology Rorer Group, Inc. developed pharmaceutical preparations. It also manufactured and supplied medical devices. The company was headquartered in Fort Washington, PA. | Health Technology |
Elixir Pharmaceuticals, Inc.
Elixir Pharmaceuticals, Inc. Investment Trusts/Mutual FundsMiscellaneous Elixir Pharmaceuticals, Inc. operates as a holding company with interest in manufacturing and developing biopharmaceutical products for the treatment of metabolic diseases such as diabetes and obesity. The company was founded by Leonard Guarente, Cynthia J. Kenyon, Cindy Bayley, Louis Kunkel, Annibale Puca, and Thomas Perls in 1999 and is headquartered in Cambridge, MA. | Miscellaneous |
